Case IH and New Holland Agriculture win four ASABE 2023 Innovation Awards

London, January 11, 2023

Case IH and New Holland, global agricultural brands of CNH Industrial, have won four 2023 ASABE AE50 awards from the American Society of Agricultural and Biological Engineers (ASABE). These prestigious awards honor the year’s 50 most innovative products and systems engineered for the food and agricultural industries.

Case IH won its first award for the Early Riser® 2150S Front-Fold Split-Row Planter. It features a 50-inch split-row offset (front to back) design which maximizes residue flow and minimizes residue plugging – for more efficient and agronomic operation. The planter delivers accurate row unit ground following, seed placement and depth. All settings can be made directly from the cab allowing the farmer to easily apply the necessary adjustments to maximize productivity.

New Steiger® Series Tractor Three-Point Hitch system is the brand’s second AE50-winning product. It is designed to maximize the power and lift capacity of wide-frame Steiger series tractors. The innovative system now has a 20,000-pound lift capacity and increased maximum lift height which will allow the tractor to tackle a wider variety of tasks on the farm.

New Holland Agriculture was recognized for its 2023 Guardian™ Front Boom Sprayer with PLM Intelligence™ which features all-new electronic controls and offboard connectivity. Upgrades include liquid management system controls in the cab and fill station, and a full integration to the Precision Land Management (PLM) intelligence infrastructure offered by New Holland PLM connect systems and Raven Slingshot offboard interfaces. The PLM intelligence system benefits the customer by remotely providing diagnostics, service information and agronomic data straight to a phone, tablet, or home office – meaning they can make even more timely decisions to enhance overall profitability and productivity.

Pro-Belt™ Series Variable Chamber Round Balers won New Holland’s second award. The balers are equipped with the ActiveDrop™ rotor drop floor which provides the durability required by baling contractors and high use farmers. The ActiveDrop rotor drop floor provides an alert to the operator when the load on the rotor is approaching maximum capacity. This allows the operator to adjust their baling speed to avoid rotor overloading and increases overall productivity.

These awards recognize CNH Industrial’s ongoing development of customer-inspired, innovative products.

CNH Industrial (NYSE: CNHI / MI: CNHI) is a world-class equipment and services company. Driven by its purpose of Breaking New Ground, which centers on Innovation, Sustainability and Productivity, the Company provides the strategic direction, R&D capabilities, and investments that enable the success of its global and regional Brands. Globally, Case IH and New Holland Agriculture supply 360° agriculture applications from machines to implements and the digital technologies that enhance them; and CASE and New Holland Construction Equipment deliver a full lineup of construction products that make the industry more productive. The Company’s regionally focused Brands include: STEYR, for agricultural tractors; Raven, a leader in digital agriculture, precision technology and the development of autonomous systems; Flexi-Coil, specializing in tillage and seeding systems; Miller, manufacturing application equipment; Kongskilde, providing tillage, seeding and hay & forage implements; and Eurocomach, producing a wide range of mini and midi excavators for the construction sector, including electric solutions.

Across a history spanning over two centuries, CNH Industrial has always been a pioneer in its sectors and continues to passionately innovate and drive customer efficiency and success. As a truly global company, CNH Industrial’s 37,000+ employees form part of a diverse and inclusive workplace, focused on empowering customers to grow, and build, a better world.

For more information and the latest financial and sustainability reports visit: cnhindustrial.com

For news from CNH Industrial and its Brands visit: media.cnhindustrial.com

Media contacts:

Rebecca Fabian Anna Angelini
North America United Kingdom
Tel. +1 312 515 2249 Tel. +44 (0)7725 826 007

[email protected]

Attachments

GlobeNewswire Distribution ID 1000776793

IIBA and HPRA Announce Strategic Partnership

New Certificate Program Incorporates Business Analysis to Enhance HR Function, Improving Business Outcomes

TORONTO, Jan. 11, 2023 (GLOBE NEWSWIRE) — The International Institute of Business Analysis™ (IIBA®) and the Human Resources Professionals Association (HRPA) are proud to announce their strategic partnership. HRPA, serving the Ontario Province, have been advocating for the human resources profession for over 40 years to ensure that HR professionals have the most up-to-date tools and advanced skills needed to lead workplaces into the future. IIBA, with 30,000 members around the world, is leading the global business analysis community and is shaping professional standards to achieve better outcomes through better analysis.

Business analysis skills are strategically important to today’s CHRO tasked with taking on complex organizational challenges, as expectations of the HR function are increasing for advanced strategic thinking in defining solutions that deliver organizational value. HR needs a playbook of repeatable processes of uncovering the real business issues to solve, better techniques for determining solutions that are impactful, and a focused way of assembling compelling business cases that gain organizational support. To help HR professionals gain these skills, HRPA partnered with IIBA.

The partnership between IIBA and HRPA is a pivotal relationship that emphasizes the value of leveraging analysis and data to drive business decisions and optimize HR practices. Through the combination of cutting-edge research, industry insights, and best practices, this partnership helps to ensure that HR professionals have the necessary business analysis skills and knowledge to effectively lead their organizations into the future.

“Coming into the post-pandemic era there is a need for workplaces to increase learning agility, simplify cumbersome people processes, radically transform the employee experience, and turn their attention to increased organizational effectiveness to evolve within the new world of work,” said Kris Tierney, Vice President HR and Learning, HRPA. “We wanted to offer our members a program built on the proven standards of IIBA and highlight for HR professionals the value of business analysis in remarkably improving enterprise outcomes.”

To help the HR profession meet the challenges of this new world and lead at a higher level, HRPA in association with the IIBA have built the Radical HR: Upskilling from Service Provider to Solution Expert program using the foundation of IIBA’s Entry Certificate in Business Analysis™ (IIBA-ECBA). This innovative course is a five-module certificate program designed to enable organizational change by empowering participants to identify opportunities, define needs, and recommend solutions to deliver stakeholder value in the Human Resources field. By the end of the program, participants will receive the Human Resources Solutions Certificate (HRSC) and be equipped to sit IIBA’s ECBA™ exam.

“This program is focused on giving HR practitioners’ practical business analysis tools to assist in navigating complex projects and change. These skills will set up HR diagnostics to be clear and strategic for your clients and leaders,” said Mary Madigan Lee, Chief People Officer, City of Toronto.

“HRPA and IIBA realized business analysis skills needed to be stronger in HR professionals to support the pace of change faced by their members. The partnership with HRPA brings the value of business analysis to achieve better business outcomes to HR professionals in a way that is practical and resonates for their unique needs,” said Keith Ellis, Chief Engagement and Growth Officer, IIBA. “What makes this program so unique is that it provides a clear path for HR professionals to transform from being a service provider to being the solution designer, influencer, and change partner that top leadership requires.”

73% of pilot participants felt they gained a sense of confidence to impact and influence change after completing the course.1 All participants believe that business analysis techniques and skills are essential to a high-functioning HR department. The tools learned within this program will help participants better use business analysis foundations to conduct comprehensive needs analyses, create evidence-based solutions, and support organizational transformation, employee development and performance management, succession planning, and other key practices. Participants will advance their careers by gaining the necessary skills to deliver value-creating solutions that meet stakeholder needs across the business. Individuals exiting the program report have a feeling of greater individual and team effectiveness in evolving core HR processes, as well as greater confidence, to tackle complex change initiatives.

Follow the link below to register for the course:
Radical HR: Upskilling from Service Provider to Solution Expert

Business analysis provides tremendous value to a wide range of industries and roles by helping organizations sense and enable change by defining needs and recommending solutions that deliver value. Join IIBA as a strategic partner and become part of a global network of experts who work towards delivering better outcomes through business analysis.

To learn more about IIBA’s Strategic Partnerships please visit https://www.iiba.org/organizational-programs/strategic-partnerships/.

About IIBA
International Institute of Business Analysis™ (IIBA®) is a professional association leading the global business analysis community to achieve better outcomes through better analysis. With over 30,000 Members and certified professionals, and more than 120 Chapters, 1,200 volunteers, and 600 partners worldwide, IIBA supports the recognition of the profession within organizations, enables networking and community engagement, provides foundational standards and resources, and offers internationally recognized certification programs for career advancement. For more information, visit iiba.org.

About HPRA
At the Human Resources Professionals Association, we believe that better HR makes business better. The HRPA ensures that our 24,000 members and students have the most up-to-date tools and the advanced skills to lead our workplaces into the future. We regulate HR professionals in the public interest. Our members are held to the province’s highest standards, so Ontario workplaces can trust us to help unlock business growth and optimize employee potential. Learn more at hrpa.ca.

  1. Source: IIBA post course-assessment of pilot participants

Media Contacts
Shyra Wells, Communications & Media Specialist
IIBA
[email protected]
+1 (289) 212-3657

Public Relations & Communications Department
HRPA
[email protected]

GlobeNewswire Distribution ID 8728108

Capsa Healthcare Acquires Tryten Technologies to Strengthen Its Leadership Position in Mobile Computing

COLUMBUS, Ohio, Jan. 11, 2023 (GLOBE NEWSWIRE) —  Capsa Healthcare, a leading innovator in healthcare delivery solutions for hospitals, long-term care, and retail pharmacy providers, announced the acquisition of Tryten Technologies Inc., a designer and manufacturer of lightweight, easy to maneuver mobile cart solutions. Tryten is based in Langley, British Columbia.

A Media Snippet accompanying this announcement is available by clicking the image or link below.

Tryten Medical Carts Snippet: 3 Photos Tryten CaregiversCapsa’s purchase of Tryten is the company’s second major brand acquisition in the last year, and strategically addresses several healthcare industry trends. Today’s hospitals and clinics are striving to provide expanded virtual care, improved patient engagement and efficient mobility for small medical devices; Capsa now has the widest product portfolio to support these needs.

Tryten is an industry leader known for thoughtful, simple, slim-profile cart designs to support virtual care and improved patient experience in practically any care setting. In addition, Tryten provides customized cart solutions to medical device companies and healthcare solution providers so they can safely and effectively mobilize their technology devices for better clinical workflows and improved patient care delivery.

Tryten mobile computing carts are applicable for a host of applications including:

  • Ultrasound
  • Cardiology
  • Endoscopy
  • Tele Stroke
  • Virtual Interpreting/translation
  • Patient observation
  • Electronic health records
  • Patient registration and vital signs

“After observing the rapid adoption of virtual care and the expanded use of tablets and innovative technologies in healthcare, we decided that now was the right time to invest in expanding Capsa’s point-of-care solutions portfolio,” says Eric Webb, Capsa Healthcare CEO. “Tryten is a fresh, relatively new brand in the mobile workstation space, and we have every reason to believe its inclusion will help our clinical customers deliver the best care to patients in whatever setting they work.”

Understanding that computing workstation needs differ across care environments, Capsa Healthcare offers an extensive portfolio of mobile computing workstations, wall mount arm platforms, and solutions that support modern medication management. Capsa’s breadth of products include its Trio, M38e, MedLink, T7, and SlimCart mobile workstations, as well at its leading V6 wall mount solution. The addition of Tryten’s mobile carts is complementary to Capsa’s point-of-care solutions and opens a new and exciting opportunity to advance both virtual and patient-centered healthcare delivery.

“Tryten and Capsa have both worked diligently toward a similar overarching goal to improve the clinician’s ability to efficiently deliver quality care to the patient. Bringing the Tryten product line into Capsa’s portfolio is a natural fit culturally and functionally,” says Tony Janzen, Tryten CEO. “We’re excited for what the future holds as our team joins the expanding Capsa organization.”

About Capsa Healthcare

Capsa Healthcare is a worldwide leader in developing and delivering innovative healthcare solutions for a wide spectrum of care providers. With 60+ years of experience, Capsa Healthcare offers a unique ability to meet the demands of diverse healthcare environments and offers a broad range of products including medication carts, medical carts, mobile computing, and pharmacy automation solutions. Headquartered in Columbus, OH, and with a quickly growing global presence, Capsa Healthcare has 400+ employees with management, sales, and production offices throughout the world. To learn more visit www.capsahealthcare.com or call 800-437-6633.

About Tryten

Tryten Technologies Inc., based in Langley, British Columbia, designs and manufactures lightweight, versatile mobile cart solutions for a wide range of applications including video remote interpreting (VRI), virtual rounding, tele sitting, EHR workstations, and telemedicine. Tryten’s goal is to improve the patient and provider experience while reducing the cost of care, enabling value-based care where and when it is needed most.

Press Contact:
Liz Delp
Senior Marketing Manager | Capsa Healthcare
Columbus, OH U.S.A.
614.729.8012 | [email protected]

Photography Available

GlobeNewswire Distribution ID 8726727

LambdaTest launches Test Analytics to enable better decision making

Test Analytics will be available for web browser automation, app automation, and HyperExecute users. The company has also released a slew of other product updates over the last quarter.

San Francisco, Jan. 11, 2023 (GLOBE NEWSWIRE) — LambdaTest, the leading continuous quality testing cloud platform, has launched Test Analytics. Users can now add custom widgets and create dashboards to get a comprehensive view of their test execution.

The company has also released multiple other product updates over the last quarter including automation testing for OTT streaming devices, Cypress Safari Webkit Support, and support for iPhone 14 series, iPad 2022 series, Pixel 7 series, and Galaxy Z Fold4, among others.

LambdaTest Test Analytics enables DevOps teams to track the progress and quality of testing across multiple LambdaTest product lines in a single view through highly customizable dashboards thereby enabling better decision-making for companies. Users can access vital information on tests including test inconsistencies, test case health summary, browser/OS/device categorization, test trends, and test status ratio, among other data.

“Stitching together data from multiple sources is time-consuming. With LambdaTest Test Analytics, we want to enable a seamless view of test execution data for development teams. With Test Analytics, decision-makers will have all the necessary information at their fingertips,” said Mayank Bhola, Co-Founder and Head of Product, LambdaTest. “Over the last quarter, we’ve added new features to all our product lines-Selenium, Cypress, Playwright, real-time testing, real devices, etc to enable our customers to do seamless testing. We are constantly enhancing our platform to make the lives of our users easier.”

LambdaTest has also recently launched HyperExecute, a next-gen smart test orchestration platform that helps testers and developers run end-to-end automation tests at the fastest speed possible.

To know more about LambdaTest Test Analytics, please visit, https://www.lambdatest.com/test-analytics

About LambdaTest

LambdaTest is a continuous quality testing cloud platform that helps developers and testers ship code faster. Over 10,000+ customers and 2+ million users across 130+ countries rely on LambdaTest for their testing needs.

LambdaTest platform provides secure, scalable, and insightful test orchestration for customers at different points in their DevOps (CI/CD) lifecycle:-

Browser & App Testing Cloud allows users to run both manual and automated tests of web and mobile apps across 3000+ different browsers, real devices, and operating system environments.

HyperExecute helps customers run and orchestrate test grids in the cloud for any framework and programming language at blazing-fast speeds to cut down on quality test time, helping developers build software faster.

For more information, please visit, https://lambdatest.com

For further information please contact the LambdaTest press office: [email protected].

GlobeNewswire Distribution ID 8727882

Zenas BioPharma Announces First Patient Dosed in Phase 3 Clinical Study of Obexelimab for the Treatment of Immunoglobulin G4-Related Disease (IgG4-RD)

Global Phase 3 INDIGO study will evaluate the efficacy and safety of obexelimab in patients with IgG4-RD, a chronic and serious fibroinflammatory disease typically affecting multiple organs

IgG4-RD is the first of several potential disease indications to be pursued for obexelimab given its unique non-depleting, B-cell inhibition

WALTHAM, Mass., Jan. 11, 2023 (GLOBE NEWSWIRE) — Zenas BioPharma, a global biopharmaceutical company committed to becoming a leader in the development and commercialization of immune-based therapies, today announced that the first patient has been dosed in the INDIGO Phase 3 registrational study of obexelimab. The INDIGO study will evaluate the clinical efficacy and safety of obexelimab treatment in the prevention of IgG4-related disease (IgG4-RD) flare. Obexelimab is a high-affinity bifunctional antibody that inhibits B-cell lineages by simultaneously binding to CD19 and FcƳRIIB, thereby downregulating B-cell activity in patients with autoimmune diseases associated with autoantibodies, such as IgG4-RD.

“IgG4-RD is a chronic and serious fibroinflammatory condition that can affect nearly any organ system and can have a profound impact on many patients, leading to severe organ damage or death,” said Hua Mu, M.D., Ph.D., Chief Executive Officer at Zenas. “There are no currently approved treatments for patients living with IgG4-RD. Based upon the promising data from a Phase 2 study of obexelimab in IgG4-RD patients, we are excited to continue to evaluate the potential of obexelimab in the INDIGO study.”

About the INDIGO Study

The INDIGO study is a global multicenter, randomized, double-blind, placebo-controlled study enrolling up to 200 adults with active IgG4-RD signs/symptoms (i.e., flare) that require steroid therapy. Patients will be randomized in a ratio of 1:1 to receive either obexelimab or placebo, administered as subcutaneous injections.

The primary endpoint of INDIGO is time to first IgG4-RD flare (defined as the reappearance of previous signs/symptoms or appearance of new signs/symptoms of IgG4-RD) that requires initiation of rescue therapy from randomization to Week 52. Safety will be evaluated throughout the study duration.

More information on the INDIGO study (NCT05662241) is available at clinicaltrials.gov.

About Obexelimab

Obexelimab is an investigational Phase 3-stage, novel bifunctional antibody with first-in-class potential that inhibits B-cell lineages that express CD19. Simultaneous binding to CD19 and FcƳRIIB by obexelimab mimics a natural antigen-antibody complex and downregulates B cell activity. In several early-stage clinical studies, 198 subjects were treated with obexelimab. In these clinical studies, the molecule demonstrated effective inhibition of B cell function without depleting the cells and generated an encouraging treatment effect in patients with multiple autoimmune diseases. Zenas acquired exclusive worldwide rights to obexelimab from Xencor, Inc.

About IgG4-RD

IgG4-RD is a chronic and serious fibroinflammatory disease typically affecting multiple organs (e.g., pancreas, liver, kidney, bile duct, salivary and lacrimal glands). Approximately 20,000 people are diagnosed with IgG4-RD in the US, with similar prevalence rates across geographies. Many patients have some degree of irreversible organ damage at the time of diagnosis. Although nearly all patients initially respond to glucocorticoid (GC) therapy, a majority of patients will relapse/flare within a few months of discontinuing treatment, requiring rescue therapy. Chronic GC therapy is also associated with toxicity in many patients.

About Zenas BioPharma

Zenas BioPharma is a global biopharmaceutical company committed to becoming a leader in the development and commercialization of immune-based therapies for patients around the world. With clinical development and operations globally, Zenas is advancing a deep and balanced global portfolio of potential first- and best-in-class autoimmune therapeutics in areas of high unmet medical need while meeting the value requirements of the dynamic global healthcare environment. The company’s pipeline continues to grow through our successful business development strategy. Our experienced leadership team and network of business partners drive operational excellence to deliver potentially transformative therapies to improve the lives of those living with autoimmune and rare diseases. For more information about Zenas BioPharma, please visit www.zenasbio.com and follow us on Twitter at @ZenasBioPharma and LinkedIn.

Investor and Media Contact:
Joe Farmer, President & COO
Zenas BioPharma
[email protected]

GlobeNewswire Distribution ID 8727743

The Yacht Club of Monaco Celebrates the 70th Anniversary with a Packed Programme of Festivities

The Yacht Club of Monaco Celebrates the 70th Anniversary with a Packed Programme of Festivities

The season begins with the 13th Monaco Optimist Team Race. Starting January the 11th, 64 under-14 sailors representing 16 nations gather to dispute a unique race.

MONACO, Jan. 11, 2023 (GLOBE NEWSWIRE) — January kicks off a busy events programme for 2023, as the Yacht Club de Monaco celebrates 70 years since it was set up by Prince Rainier III. Presided since 1984 by HSH Prince Albert II of Monaco, this private club continues to honour its public service remit by organising world class events to promote the destination. The agenda fits within its ‘Monaco, Capital of Advanced Yachting’ approach, initiated by YCM to position the Principality as a centre of excellence in this sector.

The season begins with the 13th Monaco Optimist Team Race. Starting January the 11th, 64 under-14 sailors representing 16 nations gather to dispute a unique race. The format is unusual for an Optimist regatta, a match race being like a duel on water between teams of four as opposed to a fleet race of individuals. The result is 120 races in the knock-out rounds leading up to the finals and requiring finely tuned skills, tactics and above all teamwork. In the run up to the contest to hone their race techniques, teams are already on site to take part in an International Clinic (9-11 January 2023) supervised by Chris Atkins.

The Spotlight then will be on one designs, with the 10th Monaco Sportsboat Winter Series (2-5 February) and 39th Primo Cup-Trophée Credit Suisse (2-5 March). The best J/70 teams, who have established their training base in the Principality, will meet again this month for Act III of the 10th Monaco Sportsboat Winter Series of monthly regattas, which has become a fixture on the calendar for international teams. Races are set to be tight for the fleet, currently led by YCM’s Ludovico Fassitelli on Junda followed by Graeme Peterson (Moonlight II) and Stefano Roberti (Piccinina), also from YCM.

Moving on to March, during the Monaco Ocean Week (20-26), organised by the Prince Albert II of Monaco Foundation, Monaco Oceanographic Institute and the Scientific Centre of Monaco, YCM will be responsible for the yachting component of this week focused on protecting the oceans. On Thursday 23rd March at the YCM there will be four events, starting with the 12th Environmental Symposium dedicated to the 10th Monaco Energy Boat Challenge on the theme ‘Encouraging the Future for a more Sustainable Yachting’. This highlight precedes the 27th Captains’ Forum that brings owners, captains and superyacht industry leaders together, the theme this time will be ‘Superyacht Commitment: Management, Leadership & Mentoring’.

After the success of the Monaco Smart & Sustainable Marina Rendezvous (next one at YCM, 24-25 September 2023), M3 (Monaco Marina Management) is launching the first Monaco Smart Yacht Rendezvous, a networking event that continues on Friday 24th March culminating in the Smart Innovative Yacht Awards. Thursday 23rd March concludes with the 3rd YCM Explorer Awards by La Belle Classe Superyachts. Organised under the presidency of HSH Prince Albert II since 2019, it has been recognising owners who stand out for their commitments to protect the marine environment, be it in the design of their yacht or its navigation.

L’Art de Vivre la Mer is the motto of the Yacht Club de Monaco. To illustrate it and to put the spotlight on gourmet cuisine at sea as being another facet of yachting professions, the YCM will organise on 30th March the 4th edition of the Superyacht Chef competition, with an international jury chaired by the two-time three Michelin star chef Yannick Alléno.

In July, the 10th Monaco Energy Boat Challenge will take place (3-8 July). Helping build tomorrow’s future is a key priority for YCM, an ambition it pursues through the Monaco Energy Boat Challenge for alternative energy sources. For the last ten years, this event has been bringing young engineers from technical colleges and universities the world over into contact with yachting industry players.

As a Club that’s very attached to its sailing heritage, YCM will be organising the 16th Monaco Classic Week –La Belle Classe (13-16th September). This unique biennial offers a journey through time, synonymous with the celebrated Art de Vivre le Mer lifestyle at sea. For the public it’s an opportunity to see some of the world’s most prestigious classic sailing yachts, period motor-yachts and vintage motorboats that create such a spectacle in the YCM Marina. This edition also celebrates the 100th anniversary of the birth of Prince Rainier III, who founded YCM in 1953 and was so passionate about the sea and boats.

For more information:

LaPresse SpA Communication and Press Office Director
Barbara Sanicola [email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/0b602ae2-c322-464c-a8fb-12ac6b3299f1

The photo is also available at Newscom, www.newscom.com, and via AP PhotoExpress.

GlobeNewswire Distribution ID 8727406